The firm is a venture capital group based in New Jersey with a dedicated life sciences fund that invests primarily at the Seed stage. The fund typically commits around USD $1 million per company and is flexible in taking either a lead or co-investor role. Its geographic focus spans North America and Europe.
Within life sciences, the fund targets therapeutics, medical technology, digital health, and biotech ecosystem companies that address age-related diseases such as cardiovascular disease, cancer, respiratory illnesses, dementia, Alzheimer’s, diabetes, and kidney disease.
On the therapeutics side, the fund emphasizes “repair and replace” technologies, including regenerative medicine, gene therapy, and immunotherapy. In medtech, it is particularly interested in wearables, biosensors, and remote patient monitoring solutions. For digital health, the focus extends to AI-driven drug discovery and clinical trial optimization. Within the broader biotech ecosystem, areas of interest include bioprinting, biomaterials, and novel drug delivery systems.
The firm seeks companies built on strong scientific foundations, offering innovative and scalable solutions. It values management teams with diverse expertise across science, business development, administration, and marketing.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment